Clinical Trial

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 4, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-19.
Trial Details
NCT Number NCT06747936
Lead Sponsor Addpharma Inc.
Conditions Primary Hypercholesterolemia
Enrollment 110 participants
Start Date 2025-02
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-02-04